Cardiff and Vale University Health Board, Cardiff, UK
Health and Care Research Wales, Cardiff, UK.
BMJ Paediatr Open. 2024 Oct 4;8(1):e002778. doi: 10.1136/bmjpo-2024-002778.
Febrile infants under 3 months of age are at risk of invasive bacterial infection (IBI). It is currently unclear if testing for respiratory viruses may have a role in IBI risk stratification. If found to be associated with the likelihood of IBI, respiratory viral point-of-care testing may improve patient and caregiver experience, reduce costs and enhance antimicrobial stewardship.
This is a study protocol for a systematic review and meta-analysis that aims to answer the following question: ?A search strategy will include MEDLINE, EMBASE, Web of Science, The Cochrane Library and grey literature. Abstracts and then full texts will be independently screened for selection. Data extraction and quality assessment will be completed by two independent authors.The primary objective is to analyse the ability of a positive respiratory viral test to identify the overall risk of IBI. The secondary objective is to perform a subgroup analysis to investigate how the risk stratification alters based on other variables including virus type, patient characteristics and the presence of an identified source of fever.Bivariate random-effects meta-analysis will be undertaken. Diagnostic odds ratios (OR), sensitivity, specificity and positive and negative likelihood ratios will be calculated. The degree of heterogeneity and publication bias will be investigated and presented.
Ethical approval is not required. We will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to disseminate the study results through publication and conference presentations.
This protocol is registered in PROSPERO-ID number: CRD42023433716.
3 个月以下发热婴儿存在侵袭性细菌感染（IBI）风险。目前尚不清楚检测呼吸道病毒是否有助于 IBI 风险分层。如果发现与 IBI 的可能性相关，呼吸道病毒即时检测可能会改善患者和照护者的体验，降低成本并加强抗菌药物管理。
这是一项系统评价和荟萃分析的研究方案，旨在回答以下问题：一项搜索策略将包括 MEDLINE、EMBASE、Web of Science、The Cochrane Library 和灰色文献。将独立筛选摘要和全文以进行选择。数据提取和质量评估将由两名独立作者完成。主要目标是分析阳性呼吸道病毒检测识别 IBI 总体风险的能力。次要目标是进行亚组分析，以调查风险分层如何根据其他变量（包括病毒类型、患者特征和已确定的发热源）发生变化。将进行双变量随机效应荟萃分析。将计算诊断比值比（OR）、敏感性、特异性以及阳性和阴性似然比。将调查和呈现异质性和发表偏倚的程度。
不需要伦理批准。我们将遵循系统评价和荟萃分析的首选报告项目，通过发表和会议演示来传播研究结果。
PROSPERO 注册号：本方案在 PROSPERO-ID 号：CRD42023433716 中注册。
